Nectin‐4 Expression in Prostatic Adenocarcinoma: An Immunohistochemical Study
The Prostate · 2025
DOI: 10.1002/pros.24846 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Prostate, 2025. Verfasst von Ezra G Baraban und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Johns Hopkins Hospital, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Adenocarcinoma, Cell Adhesion Molecules. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: This work was also supported by NIH/National Cancer Institute (NCI) Specialized Programs of Research Excellence (SPORE) in Prostate Cancer grant P50CA58236 Pat…, NCI NIH HHS.
Abstract (Originalsprache)
Background
The Nectin‐4 directed antibody drug conjugate enfortumab vedotin (EV) has emerged as frontline systemic therapy in combination with immune checkpoint blockade for urothelial carcinoma (UC), capitalizing on the ubiquitous expression of this protein in UC. There is limited data available regarding expression of Nectin‐4 by immunohistochemistry in prostate cancer, but this is of interest as a substantial number of UC patients likely to receive EV have concomitant prostate cancer.
Methods
Nectin‐4 protein expression was evaluated by immunohistochemistry in tissue microarrays encompassing a cohort of 302 prostatic adenocarcinomas spanning Grade Groups 1–5. Intensity of expression was scored from 1 (weak) to 3 (intense staining readily apparent at low magnification). H ‐scores were calculated by multiplying the percentage of cells staining by the intensity of expression.
Results
Nectin‐4 expression was frequently observed in benign prostate tissue (86% of cases, mean H ‐score of 40, median 20, interquartile range [IQR]: 10–60) and in prostatic adenocarcinoma (91% of cases, mean H ‐score of 90, median 70, IQR: 20–150). Significant differences in Nectin‐4 expression among prostatic adenocarcinoma Grade Groups 1–5 were not observed. Across all prostatic adenocarcinomas evaluated, the mean Nectin‐4 H ‐score of 90 was statistically significantly higher than the mean H‐score of 40 observed in benign prostate tissue ( p < 0.001). Three of four prostatic ductal adenocarcinomas showed Nectin‐4 expression, with a median H ‐score of 250 (IQR: 152–300).
Conclusions
Nectin‐4 protein expression is common in benign prostate tissue and prostatic adenocarcinoma. These findings provide a rationale for future studies investigating potential activity of EV in prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Johns Hopkins Hospital, Baltimore, Maryland, USA.
- Department of Medical Oncology, Johns Hopkins Hospital, Baltimore, Maryland, USA.
- Department of Urology, Johns Hopkins Hospital, Baltimore, Maryland, USA.
ORCID-Profile: Ezra G Baraban, Eugene Shenderov, Samuel R Denmeade
Förderung
- This work was also supported by NIH/National Cancer Institute (NCI) Specialized Programs of Research Excellence (SPORE) in Prostate Cancer grant P50CA58236 Pat…
- NCI NIH HHS
Zitieren
APA
Baraban, E. G., Vlachou, E., Patel, S., Kates, M., Johnson, B., Smith, A., Shenderov, E., Sharma, S., Denmeade, S. R., Brame, A., Han, M., De Marzo, A. M., Matoso, A., & Hoffman-Censits, J. (2025). Nectin‐4 Expression in Prostatic Adenocarcinoma: An Immunohistochemical Study. The Prostate. https://doi.org/10.1002/pros.24846
Vancouver
Baraban EG, Vlachou E, Patel S, Kates M, Johnson B, Smith A, et al. Nectin‐4 Expression in Prostatic Adenocarcinoma: An Immunohistochemical Study. The Prostate. 2025. doi:10.1002/pros.24846
BibTeX
@article{Baraban2025,
author = {Baraban, Ezra G and Vlachou, Evangelia and Patel, Sunil and Kates, Max and Johnson, Burles and Smith, Armine and Shenderov, Eugene and Sharma, Shivang and Denmeade, Samuel R and Brame, Alex and Han, Misop and De Marzo, Angelo M and Matoso, Andres and Hoffman-Censits, Jean},
title = {Nectin‐4 Expression in Prostatic Adenocarcinoma: An Immunohistochemical Study},
journal = {The Prostate},
year = {2025},
doi = {10.1002/pros.24846}
}
EUVIMED